表紙
市場調查報告書

MAP激酶交互作用絲胺酸/蘇氨酸磷蛋白激酶2 :開發中產品分析

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 365810
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
MAP激酶交互作用絲胺酸/蘇氨酸磷蛋白激酶2 :開發中產品分析 MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 53 Pages
簡介

本報告提供以MAP激酶交互作用絲胺酸/蘇氨酸磷蛋白激酶2為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

MAP激酶交互作用絲胺酸/蘇氨酸磷蛋白激酶2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • eFFECTOR Therapeutics, Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Selvita S.A.

藥物簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1953TDB

Summary:

According to the recently published report 'MAP Kinase Interacting SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019'; MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - MAP kinase-interacting serine/threonine-protein kinase 2 is an enzyme encoded by the MKNK2 gene. It phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. It plays a role in the response to environmental stress and cytokines. It appears to regulate translation by phosphorylating EIF4E thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. It triggers EIF4E shuttling from cytoplasm to nucleus. It acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis.

The report 'MAP Kinase Interacting SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Discovery stages are 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Gallbladder Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammation, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Uveal Melanoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Transitional Cell Cancer (Urothelial Cell Cancer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)
  • The report reviews MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Overview
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • AUM Biosciences Pte Ltd
    • eFFECTOR Therapeutics Inc
    • Eli Lilly and Co
    • Merck & Co Inc
    • Oncodesign SA
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Drug Profiles
    • AUM-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETC-17804452 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Mnk2 for Acute Myeloid Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MKNK1 and MKNK2 for Oncology and Unspecified Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MKNK2 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tomivosertib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Dormant Products
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 29, 2019: eFFECTOR Therapeutics to present data on Tomivosertib at AACR 2019 annual meeting
      • Jan 14, 2019: Research published in Nature Medicine demonstrates the immunological effects of Tomivosertib, including inhibiting production of checkpoint protein PD-L1 and increasing T Cell Infiltration into tumors
      • Dec 11, 2018: eFFECTOR initiates dosing in phase 2 trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
      • Jul 27, 2018: eFFECTOR initiates dosing of eFT508 (tomivosertib) in a phase 2 add-on (CPI-A) trial in combination with checkpoint inhibitors to treat patients with insufficient response to checkpoint inhibitors alone
      • Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin's Lymphoma
      • May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
      • Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
      • Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting
      • Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics' Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
      • Dec 05, 2017: Oncodesign Reports Positive Results for Its MNK1/2 Program
      • Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
      • Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
      • Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017
      • Apr 10, 2017: Cancer Genetics is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
      • Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AUM Biosciences Pte Ltd, H2 2019
  • Pipeline by eFFECTOR Therapeutics Inc, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Oncodesign SA, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
Back to Top